These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46 related articles for article (PubMed ID: 9309140)
21. MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Woodings JA; Sharp SJ; Machesky LM Biochem J; 2003 Apr; 371(Pt 2):463-71. PubMed ID: 12570871 [TBL] [Abstract][Full Text] [Related]
22. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Nur-E-Kamal MS; Kamal JM; Qureshi MM; Maruta H Oncogene; 1999 Dec; 18(54):7787-93. PubMed ID: 10618719 [TBL] [Abstract][Full Text] [Related]
23. Properties of an ezrin mutant defective in F-actin binding. Saleh HS; Merkel U; Geissler KJ; Sperka T; Sechi A; Breithaupt C; Morrison H J Mol Biol; 2009 Jan; 385(4):1015-31. PubMed ID: 19084535 [TBL] [Abstract][Full Text] [Related]
24. The coiled-coil domain is required for HS1 to bind to F-actin and activate Arp2/3 complex. Hao JJ; Zhu J; Zhou K; Smith N; Zhan X J Biol Chem; 2005 Nov; 280(45):37988-94. PubMed ID: 16157603 [TBL] [Abstract][Full Text] [Related]
25. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. He H; Hirokawa Y; Manser E; Lim L; Levitzki A; Maruta H Cancer J; 2001; 7(3):191-202. PubMed ID: 11419027 [TBL] [Abstract][Full Text] [Related]
26. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. Pineda-Lucena A; Ho CS; Mao DY; Sheng Y; Laister RC; Muhandiram R; Lu Y; Seet BT; Katz S; Szyperski T; Penn LZ; Arrowsmith CH J Mol Biol; 2005 Aug; 351(1):182-94. PubMed ID: 15992821 [TBL] [Abstract][Full Text] [Related]
27. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Xu XX; Yi T; Tang B; Lambeth JD Oncogene; 1998 Mar; 16(12):1561-9. PubMed ID: 9569023 [TBL] [Abstract][Full Text] [Related]
28. The C-terminus SH3-binding domain of Kv1.3 is required for the actin-mediated immobilization of the channel via cortactin. Hajdu P; Martin GV; Chimote AA; Szilagyi O; Takimoto K; Conforti L Mol Biol Cell; 2015 May; 26(9):1640-51. PubMed ID: 25739456 [TBL] [Abstract][Full Text] [Related]
29. Role of cortactin homolog HS1 in transendothelial migration of natural killer cells. Mukherjee S; Kim J; Mooren OL; Shahan ST; Cohan M; Cooper JA PLoS One; 2015; 10(2):e0118153. PubMed ID: 25723543 [TBL] [Abstract][Full Text] [Related]
30. Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Campbell DH; Sutherland RL; Daly RJ Cancer Res; 1999 Oct; 59(20):5376-85. PubMed ID: 10537323 [TBL] [Abstract][Full Text] [Related]
31. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Schuuring E; Verhoeven E; Litvinov S; Michalides RJ Mol Cell Biol; 1993 May; 13(5):2891-98. PubMed ID: 8474448 [TBL] [Abstract][Full Text] [Related]
32. Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells. Butler B; Kastendieck DH; Cooper JA Nat Immunol; 2008 Aug; 9(8):887-97. PubMed ID: 18587398 [TBL] [Abstract][Full Text] [Related]
33. Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells. Koya Y; Liu W; Yamakita Y; Senga T; Shibata K; Yamashita M; Nawa A; Kikkawa F; Kajiyama H Oncotarget; 2018 Aug; 9(66):32609-32623. PubMed ID: 30220969 [TBL] [Abstract][Full Text] [Related]
34. Hematopoietic lineage cell-specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma. Liu W; Kajiyama H; Shibata K; Koya Y; Senga T; Kikkawa F Oncol Lett; 2018 Jun; 15(6):9406-9412. PubMed ID: 29805664 [TBL] [Abstract][Full Text] [Related]
35. [HS1 and EMS1]. He H Gan To Kagaku Ryoho; 1997 Sep; 24(11):1448-53. PubMed ID: 9309140 [TBL] [Abstract][Full Text] [Related]
36. Cortactin regulates cell migration through activation of N-WASP. Kowalski JR; Egile C; Gil S; Snapper SB; Li R; Thomas SM J Cell Sci; 2005 Jan; 118(Pt 1):79-87. PubMed ID: 15585574 [TBL] [Abstract][Full Text] [Related]
37. Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation. He H; Watanabe T; Zhan X; Huang C; Schuuring E; Fukami K; Takenawa T; Kumar CC; Simpson RJ; Maruta H Mol Cell Biol; 1998 Jul; 18(7):3829-37. PubMed ID: 9632767 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the EMS1 gene and its product, human Cortactin. Schuuring E; van Damme H; Schuuring-Scholtes E; Verhoeven E; Michalides R; Geelen E; de Boer C; Brok H; van Buuren V; Kluin P Cell Adhes Commun; 1998; 6(2-3):185-209. PubMed ID: 9823470 [TBL] [Abstract][Full Text] [Related]
39. Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Lin J; Liu J; Wang Y; Zhu J; Zhou K; Smith N; Zhan X Oncogene; 2005 Mar; 24(12):2059-66. PubMed ID: 15688017 [TBL] [Abstract][Full Text] [Related]